Pfizer Oral Weight Loss Drug May be as Effective as, Quicker than Ozempic Injection by Novo Nordisk, Study Says

A new study suggests that Pfizer’s oral weight loss drug may be just as effective, if not more so, than the Ozempic injection marketed by Novo Nordisk. According to the study, Pfizer’s drug not only helps with weight loss, but it can also improve blood sugar control and cholesterol levels.

The study was conducted over a 52-week period and involved over 2,000 participants who struggled with obesity and type 2 diabetes. The participants were randomly assigned to one of three groups: one that took Pfizer’s oral drug, another that received the Ozempic injection, and a third group that was given a placebo.

The results of the study showed that both the Pfizer drug and the Ozempic injection helped participants lose a significant amount of weight. However, the Pfizer drug resulted in greater weight loss than Ozempic after 26 weeks, and it achieved the same weight loss as Ozempic after 52 weeks.

In addition to weight loss, the Pfizer drug also helped participants improve their blood sugar control and reduce their cholesterol levels. These improvements were seen as early as 4 weeks into the study and continued throughout the 52-week period.

The study also found that the Pfizer drug was generally well-tolerated by participants, with only a small percentage experiencing any adverse effects such as nausea or diarrhea.

The results of the study are particularly promising given the current obesity epidemic and the limited options available to those seeking to lose weight. While drugs like Ozempic have been shown to be effective, they require injections which can be unpleasant for some patients. An oral option like Pfizer’s drug may be a more appealing alternative for those seeking to lose weight.

It’s important to note that the study was sponsored by Pfizer, and further research will be needed to confirm the results. However, the findings suggest that Pfizer’s drug could be a game-changer in the fight against obesity and type 2 diabetes. If approved by the FDA, it would provide a new and potentially more convenient option for those seeking to improve their health and well-being.

Source